One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ...

A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced ...

Despite raising the price of its IPO twice, Caris Life Sciences Inc. left money on the table with a 33% increase in price as ...

Caris plans to use the proceeds from its IPO to pay off about $400 million worth of debt, he noted, and it also intends to ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris ...

The setback was the latest in what has become an increasingly important bet for Elon Musk. OpenAI is changing how it sells the business version of its ChatGPT chatbot, amid increasingly heated ...

Recent developments in health include Brazil's bird flu impacts harming its chicken exports, new weight-loss drugs focusing ...

Recent health news highlights include global bird flu restrictions impacting Brazilian chicken exports, advancements in ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.

A new round of workforce cuts at the Redmond, Wash.-based tech giant comes as the company makes a costly push into AI. Cancer-testing company raises $494 million in initial public offering.

Cancer-testing company raises $494 million in initial public offering.